Evidence map›Paper›PMID 41594683›Full record

ArticleBiomolecules2026

Site-Specific Aspartic Acid d-Isomerization in Tau R2 and R3 Peptide Seeds Attenuates Seed-Induced Fibril Formation of Full-Length Tau.

Genta Ito, Takuya Murata, Noriko Isoo, Toshihiro Hayashi, Naoko Utsunomiya-Tate

Abstract read
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Genta ItoDepartment of Biomolecular Chemistry, Faculty of Pharmaceutical Sciences, Teikyo University, Tokyo 173-8605, Japan.ORCID 0000-0001-6370-1099
Takuya MurataDepartment of Biomolecular Chemistry, Faculty of Pharmaceutical Sciences, Teikyo University, Tokyo 173-8605, Japan.
Noriko IsooDepartment of Physiology, School of Medicine, Teikyo University, Tokyo 173-8605, Japan.
Toshihiro HayashiDepartment of Physiology, School of Medicine, Teikyo University, Tokyo 173-8605, Japan.ORCID 0000-0003-4362-7439
Naoko Utsunomiya-TateDepartment of Biomolecular Chemistry, Faculty of Pharmaceutical Sciences, Teikyo University, Tokyo 173-8605, Japan.

Funding

Japan Society for the Promotion of Science 21K06498Teikyo University 20-02
6 · The paper itself

Abstract

The aggregation of tau protein is a central pathological event in Alzheimer's disease, and this pathology is hypothesized to spread via a prion-like mechanism driven by tau "seeds". While aggregated tau from Alzheimer's disease brains is known to contain age-related d-isomerized aspartic acid (d-Asp) residues, it remains unknown how this modification affects the seeding activity that drives disease propagation. Here, we investigated the impact of site-specific d-isomerization within R2 and R3 tau repeat-domain peptides, which form the core of tau fibrils. We demonstrate that the stereochemical integrity of these peptides is critical for their seeding function. d-isomerization at Asp314 within the R3 peptide seed severely impaired its ability to template the fibrillization of full-length tau in vitro. This finding was validated in a cellular model, where R3 seeds containing d-Asp314 were significantly less potent at inducing the formation of phosphorylated tau aggregates compared to wild-type seeds. Our results establish that Asp d-isomerization within tau seeds acts as a potent attenuator of their pathological seeding activity, suggesting this spontaneous modification may intrinsically modulate the progression of Alzheimer's disease.

Indexed as

Aspartic AcidPeptidestau ProteinsAlzheimer DiseaseHumansIsomerismPhosphorylationAspartic AcidPeptidestau ProteinsD-aspartateisomerizationtau

Identifiers

PMID41594683
PMCPMC12839334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.